Ipca Laboratories Ltd is a pharmaceutical company based in India. On October 19, 1949, the company was incorporated in Mumbai under the name The Indian Pharmaceutical Combine Association Limited. The company was named Ipca laboratories Ltd in 1964, and then it was changed to Ipca Laboratories Private Limited. However, in 1988, it was again changed back to Ipca Laboratories Ltd.
Ipca laboratories Ltd is listed on the Bombay Stock Exchange with the code 524494 and on the National Stock Exchange with the symbol IPCALAB. The company had a market capitalisation of Rs 22,016 crore on November 18, 2022.
Ipca Laboratories Ltd manufactures over 350 formulations and 80 active pharmaceutical ingredients (APIs). It has 17 manufacturing units across India, and its products are exported to 100 countries. Some APIs that Ipca Laboratories Ltd manufactures are Atenolol, Chloroquine phosphate, Chlorthalidone, Furosemide, and Hydroxychloroquine sulfate. The company has introduced a number of medicine brands, such as Zerodo, Perinorm, Tenoric, Lumerax, and Folitrax, to name a few. The subsidiary companies of Ipca laboratories Ltd are Ipca Pharmaceuticals Inc, Ipca laboratories (UK) Ltd, and Tonira Exports Ltd.
On November 17, 2022, Ipca Laboratories Ltd’s share price closed at Rs 867.80. The share prices of Ipca laboratories Ltd have risen by 52.29% over the past three years and fallen by 16.63% in the past 12 months. The share’s 52-week high was Rs 1,128.50, and the 52-week low was Rs 831.05 as of November 18, 2022.
In the third quarter of 2022, the company’s revenue was Rs 1,601 crore, which is 0.95% more than the previous quarter. The company had the best quarter in September 2021, with a profit of Rs 250 crore. The profit in the September quarter of 2022 was Rs 144 crore.
As of November 18, 2022, 46.29% of Ipca Laboratories Ltd’s shares are owned by the promoters, followed by mutual funds and foreign institutional investors with 29.71% and 10.55% company shares, respectively.
Premchand Godha is the chairman and managing director of the company, Ajit Kumar Jain is the joint managing director, and Pranay Godha and Prashant Godha are executive directors.
Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code: 07730), BSE Ltd (Member Code: 103) and Member of Multi Commodity Exchange of India Ltd.(Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Ms. Mamta Shetty, Contact number: 022-40701022, E-mail address: firstname.lastname@example.org. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Such representations are not indicative of future results. The securities quoted are exemplary and are not recommendatory. Investors should consult their financial advisers if in doubt about whether the product is suitable for them. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.